1. Home
  2. Bills
  3. H.R. 1672

H.R. 1672 · 119th Congress · 2025–2026

Maintaining Investments in New Innovation Act

H.R. 1672 in the 119th Congress (2025–2026) was introduced on Feb 27, 2025, sponsored by Donald G. Davis with 51 co-sponsors.

During the 119th Congress (2025–2026), Donald Trump was president, and Republicans held majorities in both the House and Senate.

Status
Introduced
Introduced
Feb 27, 2025
Co-sponsors
51
Policy area
Health

What it does

Maintaining Investments in New Innovation Act This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026.

Summary by the nonpartisan Congressional Research Service.

Sponsor

Donald G. Davis (D-NC). Co-sponsors: 7 Democrats, 44 Republicans.

Where it stands

  • IntroducedFeb 27, 2025
  • Passed the House—
  • Passed the Senate—
  • Sent to the President—
  • Became law—

Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such (Feb 27, 2025)

More bills from Donald G. Davis in the 119th Congress

Other Health bills in the 119th Congress

Committees

More

From GovInfo bill records, Congressional Research Service summaries, Voteview roll calls and lobbying reports.

Cite or embed this page

Capitol Receipts, “H.R. 1672 (119th Congress): Maintaining Investments in New…,” https://www.capitolreceipts.com/bill/119-hr-1672/maintaining-investments-in-new-innovation-act (accessed 2026-10-17).

Open the interactive version ›